Navigation Links
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc. (NASDAQ: INGN) and the Company's clinical collaborators today reported updated Phase 2 data demonstrating a significant correlation between abnormal p53, tumor responses and increased survival following ADVEXIN(R) therapy in patients with recurrent squamous cell carcinoma of the head and neck. The data (Abstract #6057) were presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

Tumor responses were assessed in 112 patients with recurrent head and neck cancer who received ADVEXIN. Overall, the percentages of patients with tumor responses defined by reductions in bi-dimensional tumor area on CT scan of 50 percent, 25 percent, 10 percent or stable disease for more than 2 treatment cycles were 6 percent, 7 percent, 12 percent and 22 percent, respectively. Median survival for these responder populations were 41, 17, 15 and 10 months, respectively. There was a statistically significant increase in median survival for each of the responder populations compared to the 6 month median survival of the non-responders (p less than 0.0016).

"The 41 month median duration of survival for the patients with a 50 percent or greater reduction in tumor size is very impressive and significantly greater than the six month median survival of non-responders that is typical for patients with recurrent tumors," said John Nemunaitis, M.D., Medical Director, Mary Crowley Medical Research Center. "Our findings are also consistent with a growing body of data that even smaller reductions in tumor size are clinically meaningful and are associated with increased survival."

The presentation also included data demonstrating that the predictive abnormal p53 biomarker was associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients wi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:11/28/2014)... Nov. 28, 2014 /CNW Telbec/ - Ergoresearch Ltd « Ergoresearch ... of Mrs. Dominique Boudreau who will hold ... Mrs. Dominique Boudreau was acting as corporate ... similar duties for more than seven years for Laboratoire ... January 2013.  Mrs. Boudreau replaces Mr. Greco who was ...
(Date:11/28/2014)... Kan. , Nov. 28, 2014 Aratana ... company focused on the licensing or acquisition, development and ... other companion animals, today announced that it will present ... Conference, to be held December 2-3, 2014, at the ... . Steven St. Peter , ...
(Date:11/28/2014)... 28, 2014 Alimera Sciences, Inc. (NASDAQ: ... that specializes in the research, development and commercialization ... Securities Purchase Agreement with Deerfield Management and certain ... will issue shares of preferred stock to Deerfield ... million upon the satisfaction of certain closing conditions. ...
Breaking Medicine Technology:Ergoresearch announces the appointment of its new Vice Président Finance 2Ergoresearch announces the appointment of its new Vice Président Finance 3Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3
... 5, 2011 Mylan Inc. (Nasdaq: MYL ) today ... of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ ), ... due 2012 from the Nasdaq Capital Market, on which the notes ... of trading on January 28, 2011. The notes will continue to ...
... and older falls every 2.3 seconds in the U.S., and according ... cause of fatal injury in this age group. They are ... for trauma.  The growing ranks of Americans 65 and older - ... 2050 - have inspired a new technology solution that allows the ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 3
(Date:11/28/2014)... 2014 Agein.com, the Internet’s premier anti-aging web ... of the foremost experts in the industry, is releasing its ... this winter. , “The official start of winter is still ... been hit with an icy blast. After one of the ... 2015 will usher in another brutal winter,” says Dr. Kevin ...
(Date:11/28/2014)... Brosix is always making changes to its ... a more efficient, effective, and secure experience. Most recently, ... 1. The ability to setup local servers for each ... service customers around the globe. , 2. The ability ... customers that require millions of users in one network. ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Dr. ... cosmetic dermatologists , announced the addition of Dr. Bridgit ... Nolan joins the practice after having completed her dermatology ... Medicine. , Dr. Walder invited Dr. Nolan ... in medicine, surgery and cosmetic dermatology. Not only does ...
(Date:11/28/2014)... York, New York (PRWEB) November 28, 2014 ... are continuing to move forward in New Jersey’s ... claims in a consolidated litigation established there is ... Case List updated on November 18th shows 1,293 ... was created for lawsuits that allege complications resulting ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Miami's Plastic ... website. Practice founder Dr. Jeffrey Epstein ... Created using a groundbreaking WordPress platform, the site is ... , Currently, up to 75% of all prospective ... ever, these people are logging on with smartphones, tablets, ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2
... Molecular & Cell Biology at Boston University Henry M. ... at Boston University School of Medicine discovered recently a ... expression. The study describing this work titled, "Mpk1 MAPK ... Termination," appears in the March 4 issue of ...
... new, rapid blood test that could lead to early ... thousands of people stricken with fungal meningitis, a leading ... closer to market with a recent collaboration between the ... "The ability to quickly identify yeast infection in ...
... 4 (HealthDay News) -- Children are more likely to ... playgrounds in their neighborhoods, researchers report. The study ... give their opinions about outdoor public spaces in their ... children spent watching television, using the computer and playing ...
... trial process in the United States is on shaky ... are increasingly defined by specific genetic and biologic markers ... therapies grow smaller and smaller. Coupled with skyrocketing costs ... are essential in bringing new and effective therapies to ...
... THURSDAY, March 3 (HealthDay News) -- More young people are ... engaging in same-sex encounters, according to a new report detailing ... from interviews with 13,500 men and women aged 15 to ... that more than half of young people under age 24 ...
... (HealthDay News) -- The brain,s so-called reward center actually responds ... causing fear, finds a new study in mice. The ... help explain why some people are thrill-seekers. Pleasurable or ... a bridge, can trigger the production of dopamine, a neurotransmitter ...
Cached Medicine News:Health News:Novel mechanism for control of gene expression revealed 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 3Health News:To bring effective therapies to patients quicker, use the team approach 2Health News:To bring effective therapies to patients quicker, use the team approach 3Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: